The latest price target for Structure Therapeutics (NASDAQ:GPCR) was reported by Stifel on January 8, 2025. The analyst firm set a price target for $50.00 expecting GPCR to rise to within 12 months (a possible 66.83% upside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for Structure Therapeutics (NASDAQ:GPCR) was provided by Stifel, and Structure Therapeutics initiated their buy rating.

There is no last upgrade for Structure Therapeutics

There is no last downgrade for Structure Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Structure Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Structure Therapeutics was filed on January 8, 2025 so you should expect the next rating to be made available sometime around January 8, 2026.

While ratings are subjective and will change, the latest Structure Therapeutics (GPCR) rating was a initiated with a price target of $0.00 to $50.00. The current price Structure Therapeutics (GPCR) is trading at is $29.97, which is within the analyst’s predicted range.